Connor, Clark & Lunn Investment Management Ltd. Amylyx Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 880,745 shares of AMLX stock, worth $3.57 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
880,745
Previous 621,927
41.62%
Holding current value
$3.57 Million
Previous $1.18 Million
141.57%
% of portfolio
0.02%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding AMLX
# of Institutions
127Shares Held
44.4MCall Options Held
235KPut Options Held
530K-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$18.8 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$12.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$10.8 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY2.13MShares$8.61 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.02MShares$8.19 Million0.04% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $237M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...